Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Clovis and Avila enter $209mm NSCLC collaboration

Executive Summary

Avila Therapeutics Inc. (protein silencing) has granted cancer therapy and diagnostic start-up Clovis Oncology Inc. rights to develop and commercialize its epidermal growth factor receptor (EGFR) mutant-selective inhibitor (EMSI) program for non-small cell lung cancer.
Deal Industry
  • Biotechnology
    • Large Molecule
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • Includes Contract
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register